Despite the crucial role of cancer screenings in early detection and treatment, low adherence rates pose significant challenges. In addition, only four single-cancer screenings are currently recommended by the US Preventative Task Force, leaving the population vulnerable to cancers that go unscreened, which results in ~70% of cancer deaths.1
The financial implications of late-stage cancer further underscore the urgency of improving screening adherence. Metastatic cancer accounts for over half of employers' total direct cancer spend, averaging over $90,000 per impacted employee per year.2 This starkly contrasts with the significantly lower costs of treating cancers caught at stage 1,3 highlighting the importance of early detection.
Key takeaways in this infographic:
- What's behind rising costs
- The impact cancer has on your organization as a whole
- How to boost your benefit strategy to mitigate these issues